Abstract: The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher.

Abstract: The object of the present invention is to provide a novel therapeutic or preventive agent for demyelinating disease. The present invention is a therapeutic or preventive agent for demyelinating disease, containing as an active ingredient a 2-phenylthiazole compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A detection unit (10) detects a joint angle and a joint torque for causing the joint of a subject (1) to undergo passive flexion and extension movement, and an arithmetic unit (50) performs arithmetic processing on an output signal from the detection unit. The arithmetic unit divides the relationship between the joint torque and the joint angle in at least one of the extension phase and the flexion phase into two or more portions including a proximal-side portion and a distal-side portion according to a joint angle, and obtains the elastic coefficient of the joint from the relationship between the joint torque and the joint angle in at least one of the distal-side portion and the proximal-side portion. This enables distinguishing between a healthy subject and a Parkinson's disease patient with a simple configuration, without the measurement of surface myoelectric potential.

Abstract: The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher.

Abstract: The object of the present invention is to provide a novel therapeutic or preventive agent for demyelinating disease. The present invention is a therapeutic or preventive agent for demyelinating disease, containing as an active ingredient a 2-phenylthiazole compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The motor function estimating system 1000 has a memory unit 1260, a data processing unit 1220 (analyzing section), and a display unit 1400. The memory unit 1260 memorizes waveform data about the time change of fingers tapping motion that is obtained by a motion sensor attached to a subject person who does the fingers tapping motion that is repetition of the opening and closing motion of two fingers of one hand. The data processing unit 1220 analyzes the waveform data in the memory unit 1260. The display unit 1400 displays an analysis result. The data processing unit 1220 creates motion waveform based on waveform data, and plural characteristics based on the motion waveform. The data processing unit 1220 creates a motion disorder synthesis value that represents degree of motion disorder of the subject person by revising each of the plural characteristics based on characteristics of every age and synthesizing them.

Abstract: A detection unit (10) detects a joint angle and a joint torque for causing the joint of a subject (1) to undergo passive flexion and extension movement, and an arithmetic unit (50) performs arithmetic processing on an output signal from the detection unit. The arithmetic unit divides the relationship between the joint torque and the joint angle in at least one of the extension phase and the flexion phase into two or more portions including a proximal-side portion and a distal-side portion according to a joint angle, and obtains the elastic coefficient of the joint from the relationship between the joint torque and the joint angle in at least one of the distal-side portion and the proximal-side portion. This enables distinguishing between a healthy subject and a Parkinson's disease patient with a simple configuration, without the measurement of surface myoelectric potential.

Abstract: Forces applied to cause flexion and extension movements of a joint of a subject (1) are detected by at least one force sensor (20a, 20b), and a joint torque for flexing and extending the joint is calculated based on the forces. Further, a joint angle of the joint of the subject is measured by a sensor (30). Then, a change with passage of time in each of the joint torque and the joint angle during flexion and extension movements of the joint of the subject is separated into a maximal extension position static phase, a dynamic flexion phase, a maximal flexion position static phase and a dynamic extension phase, and a muscle tonus feature amount is extracted from a relationship between the joint angle and the joint torque in at least one of the dynamic flexion phase and the dynamic extension phase.

Abstract: The motor function estimating system 1000 has a memory unit 1260, a data processing unit 1220 (analyzing section), and a display unit 1400. The memory unit 1260 memorizes waveform data about the time change of fingers tapping motion that is obtained by a motion sensor attached to a subject person who does the fingers tapping motion that is repetition of the opening and closing motion of two fingers of one hand. The data processing unit 1220 analyzes the waveform data in the memory unit 1260. The display unit 1400 displays an analysis result. The data processing unit 1220 creates motion waveform based on waveform data, and plural characteristics based on the motion waveform. The data processing unit 1220 creates a motion disorder synthesis value that represents degree of motion disorder of the subject person by revising each of the plural characteristics based on characteristics of every age and synthesizing them.

Abstract: A medicine for treatment of multiple sclerosis comprising, as an effective component, ibudilast represented by the chemical formula (1) below. Ibudilast is effective to experimental autoimmune encephalomyelitis by oral administration, and is effective to multiple sclerosis which is a disease of a central nervous system.